Optimising Rare Disease Clinical Trials with Real World Data Using NLP & AI

Volv Global CEO and Founder Christopher Rudolf will speak on optimising rare disease clinical trials with Real World Data at the Rare Trials Summit 2025 in Boston in September. The development of inclusion/exclusion criteria for clinical trial protocols can make or break drug development. Can we expand medical knowledge and discover new phenotypes and biomarkers for diseases – enabling precision targeting of the right patients for recruitment – by using data-driven machine learning methodologies